financetom
Business
financetom
/
Business
/
Digital banking software firm Alkami Q3 revenue misses estimates
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Digital banking software firm Alkami Q3 revenue misses estimates
Oct 30, 2025 1:40 PM

Overview

* Alkami ( ALKT ) Q3 revenue grows 31.5% yr/yr but misses analyst expectations

* Adjusted EBITDA for Q3 rises significantly, demonstrating progress in scaling business

* Company reports GAAP net loss of $14.8 mln, up from $9.4 mln last year

Outlook

* Alkami ( ALKT ) sees Q4 revenue between $119.6 mln and $121.1 mln

* Company expects Q4 adjusted EBITDA of $16.1 mln to $17.1 mln

* Alkami ( ALKT ) forecasts full-year revenue between $442.5 mln and $444.0 mln

* Company projects full-year adjusted EBITDA of $56.0 mln to $57.0 mln

Result Drivers

* NEW CLIENTS - Successful launch of 13 new financial institutions, including six banks, contributed to revenue growth

* REGIONAL DEMAND - Demand among regional and community financial institutions continues to drive favorable pipeline and revenue opportunities

* HOLISTIC SOLUTIONS - Early momentum in demand for holistic solutions like Alkami's ( ALKT ) Digital Sales & Service Platform

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Miss $112.95 $114.30

Revenue mln mln (10

Analysts

)

Q3 Net -$14.80

Income mln

Q3 Gross 56.80%

Margin

Q3 63.70%

Adjusted

Gross

Margin

Q3 Gross $64.14

Profit mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the it services & consulting peer group is "buy"

* Wall Street's median 12-month price target for Alkami Technology Inc ( ALKT ) is $37.50, about 39.8% above its October 29 closing price of $22.59

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Update On Theratechnologies; Down More Than 5% On TSX As Q1 Net Loss Narrows, Awaits FDA Decision
Update On Theratechnologies; Down More Than 5% On TSX As Q1 Net Loss Narrows, Awaits FDA Decision
Apr 10, 2024
09:54 AM EDT, 04/10/2024 (MT Newswires) -- Theratechnologies ( THTX ) was at last look up near 6% in US premarket trade on Wednesday after reporting a narrower Q1 loss and an acceleration of the phase 1 trial of a drug for ovarian cancer. The stock's advance came after an 8.3% jump in Canada on Tuesday The net loss fell...
Lazard's Assets Under Management Rise in March From February
Lazard's Assets Under Management Rise in March From February
Apr 10, 2024
09:49 AM EDT, 04/10/2024 (MT Newswires) -- Lazard ( LAZ ) said Wednesday that its preliminary assets under management rose to $250.4 billion in March from a little over $248 billion a month earlier. The increase was attributed to a $5.3 billion gain in market appreciation that was offset by net outflows of $2.5 billion and foreign exchange depreciation of...
What's Going On With Ford Shares After It Recalled 42,652 Bronco Sport & Escape vehicles?
What's Going On With Ford Shares After It Recalled 42,652 Bronco Sport & Escape vehicles?
Apr 10, 2024
Ford Motor Company ( F ) shares are trading lower in the morning session on Wednesday. The company will recall 42,652 Bronco Sport and Escape vehicles in the U.S. due to broken fuel injectors that may leak and induce a fire, Reuters reported. National Highway Traffic Safety Administration stated that Ford plans to incorporate fuel injector leak detection into the engine control software...
Silo Pharma Says It Exercised Option to License Alzheimer's Therapeutic From Columbia University
Silo Pharma Says It Exercised Option to License Alzheimer's Therapeutic From Columbia University
Apr 10, 2024
09:53 AM EDT, 04/10/2024 (MT Newswires) -- Silo Pharma ( SILO ) said Wednesday it has exercised its option to license the Alzheimer's disease therapeutic SPC-14 from Columbia University, as part of an existing sponsored research and option agreement set up in 2021. The company said it anticipates finalizing an exclusive license agreement to develop, manufacture and distribute SPC-14 globally...
Copyright 2023-2026 - www.financetom.com All Rights Reserved